Condition
Von Hippel Lindau
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
4Total
P 2 (4)
Trial Status
Completed2
Recruiting1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06322342Phase 2Completed
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
NCT07167329Phase 2RecruitingPrimary
Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial
NCT05563272Phase 2Terminated
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
NCT00566995Phase 2Completed
Phase II Study of Vandetanib in Individuals With Kidney Cancer
Showing all 4 trials